Health ❯ Healthcare ❯ Clinical Trials

Drug Development

Phase 3 Trials Combination Therapy Eli Lilly Targeted Therapy Phase III Trials RAS Inhibitors Alzheimer's Treatments Patient Outcomes Daraxonrasib Oncology

6 ARTICLES

2w ago

Definium’s LSD-Based Therapy Posts Third Positive Phase 3 Result in GAD

The Panorama readout strengthens the company’s push toward an NDA in H1 2027 by showing a rapid, moderate clinical effect with a safety profile similar to placebo.

3 ARTICLES

2w ago

B7‑H3 Antibody‑Drug Conjugates Cut Death Risk by Half in Relapsed Small‑Cell Lung Cancer

8 ARTICLES

3w ago

FDA Clears Roche and Eli Lilly Blood Test to Help Assess Alzheimer’s-Linked Brain Changes

5 ARTICLES

last mo.

EyePoint Stock Collapses After Duravyu Misses Phase 3 Primary Endpoint

3 ARTICLES

last mo.

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

6 ARTICLES

last mo.

AbCellera’s Menopause Antibody Hits Phase 2 Goals

6 ARTICLES

2mo ago

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

7 ARTICLES

2mo ago

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

4 ARTICLES

2mo ago

Anvisa Says Retatrutida Is Unapproved as Illegal Versions Spread

3 ARTICLES

2mo ago

FDA Clears Wearable Injector Form of Sanofi’s Multiple Myeloma Drug

3 ARTICLES

2mo ago

SII and DNDi to Run International Phase III Trial of Dengue Monoclonal Antibody

7 ARTICLES

2mo ago

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

3 ARTICLES

3mo ago

Moderna Repositions as Broad mRNA Company After Investor Day Rally

3 ARTICLES

3mo ago

Study Maps How Leukemia Enters Lungs and Identifies Drug Targets

6 ARTICLES

3mo ago

Biogen to Buy RayThera for Up to $1 Billion

5 ARTICLES

3mo ago

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

Drug Development

Definium’s LSD-Based Therapy Posts Third Positive Phase 3 Result in GAD

B7‑H3 Antibody‑Drug Conjugates Cut Death Risk by Half in Relapsed Small‑Cell Lung Cancer

AstraZeneca's Tozorakimab Cuts COPD Flare‑Ups in Two Phase 3 Trials

Lilly to Buy Merida Biosciences for Up to $2.875 Billion

Novartis Pauses CAR‑T Autoimmune Trials After Three Deaths

FDA Approves First Broad RAS Inhibitor for Metastatic Pancreatic Cancer

FDA Clears Roche and Eli Lilly Blood Test to Help Assess Alzheimer’s-Linked Brain Changes

EyePoint Stock Collapses After Duravyu Misses Phase 3 Primary Endpoint

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

AbCellera’s Menopause Antibody Hits Phase 2 Goals

Never miss stories about

Drug Development

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

Anvisa Says Retatrutida Is Unapproved as Illegal Versions Spread

FDA Clears Wearable Injector Form of Sanofi’s Multiple Myeloma Drug

SII and DNDi to Run International Phase III Trial of Dengue Monoclonal Antibody

EMA Opens Rolling Review as U.S. Hospitals Start Early Access to Daraxonrasib

Moderna Repositions as Broad mRNA Company After Investor Day Rally

Study Maps How Leukemia Enters Lungs and Identifies Drug Targets

Biogen to Buy RayThera for Up to $1 Billion

Copper Compound Restores Brain Clearance Pump and Cuts Alzheimer’s Proteins in Mice

Never miss stories about

Drug Development